Zentalis Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Zentalis Pharmaceuticals's earnings have been declining at an average annual rate of -23.7%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 102.3% per year.
Key information
-23.7%
Earnings growth rate
16.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 102.3% |
| Return on equity | -50.6% |
| Net Margin | -442.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Needs To Drive Business Growth Carefully
Oct 03
Broker Revenue Forecasts For Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Are Surging Higher
Jun 19We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Jun 13Results: Zentalis Pharmaceuticals, Inc. Confounded Analyst Expectations With A Surprise Profit
May 09Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling
Apr 12We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth
Feb 29Zentalis: Leading WEE1 Developer After AstraZeneca's Exit
Feb 05Is Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Trading At A 45% Discount?
Jan 09We're Not Very Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Rate
Oct 13We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth
Jun 30We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Mar 17We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Dec 01Zentalis Pharmaceuticals promotes co-founder Kevin Bunker to chief scientific officer
Sep 27Zentalis Pharmaceuticals has a new chief medical officer
Sep 19Zentalis Pharmaceuticals (NASDAQ:ZNTL) Is In A Good Position To Deliver On Growth Plans
Aug 17Here's Why We're Not Too Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation
May 02We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Jan 12We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Oct 14Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth
Jul 02Have Insiders Sold Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Recently?
Mar 08Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth
Jan 20Revenue & Expenses Breakdown
How Zentalis Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 41 | -179 | 63 | 186 |
| 30 Jun 24 | 41 | -195 | 65 | 196 |
| 31 Mar 24 | 41 | -219 | 59 | 191 |
| 31 Dec 23 | 0 | -292 | 59 | 190 |
| 30 Sep 23 | 0 | -286 | 54 | 179 |
| 30 Jun 23 | 0 | -285 | 50 | 174 |
| 31 Mar 23 | 0 | -241 | 59 | 175 |
| 31 Dec 22 | 0 | -237 | 55 | 173 |
| 30 Sep 22 | 0 | -232 | 53 | 161 |
| 30 Jun 22 | 0 | -182 | 50 | 164 |
| 31 Mar 22 | 0 | -168 | 41 | 165 |
| 31 Dec 21 | 0 | -159 | 41 | 167 |
| 30 Sep 21 | 0 | -149 | 42 | 158 |
| 30 Jun 21 | 0 | -179 | 43 | 137 |
| 31 Mar 21 | 0 | -152 | 43 | 110 |
| 31 Dec 20 | 0 | -118 | 34 | 85 |
| 30 Sep 20 | 0 | -92 | 26 | 67 |
| 30 Jun 20 | 0 | -70 | 18 | 53 |
| 31 Mar 20 | 0 | -53 | 10 | 45 |
| 31 Dec 19 | 0 | -46 | 8 | 38 |
| 31 Dec 18 | 0 | -23 | 5 | 19 |
Quality Earnings: ZNTL is currently unprofitable.
Growing Profit Margin: ZNTL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ZNTL is unprofitable, and losses have increased over the past 5 years at a rate of 23.7% per year.
Accelerating Growth: Unable to compare ZNTL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ZNTL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: ZNTL has a negative Return on Equity (-50.61%), as it is currently unprofitable.